Product Name:

NebuPeptide™ Insulin Aspart/Insulin Degludec (Peptide Reference)

Catalog Number:

NBS-233774

Description:

NebuPeptide™ Insulin Aspart/Insulin Degludec (Peptide Reference)(CAT#NBS-233774) is synthesized in accordance with the Insulin Aspart/Insulin Degludec sequence and can be utilized for a variety of in vivo and in vitro studies, including quality control, bioactivity verification, immunization, drug development, structural analysis, etc. Nebula Biotechnology Co., Ltd. is capable of providing Leuprorelin reference peptide ranging from milligrams to kilograms.

Peptide Name:

Insulin Aspart/Insulin Degludec

Background:

Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus. It contains insulin degludec and insulin aspart. It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh. It was approved for medical use in the European Union in January 2013, and in Australia in November 2017.

Alias:

N/A

CAS Number:

1392491-77-8

Formula:

N/A

Molecular Weight:

N/A

Purity:

see COA

Solubility:

see COA

Storage & Shipment:

Store at -20℃; ship with blue ice.

For R&D use only!

To get more information, please contact us freely.